-
Mashup Score: 3Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies - 12 day(s) ago
Nicosia et al. find that CCS1477 (inobrodib), an EP300/CBP bromodomain inhibitor, induces cell-cycle arrest and differentiation in hematologic malignancy models through disrupting EP300/CBP recruitment to enhancer networks occupied by critical transcription factors. In patients with relapsed/refractory disease, CCS1477 monotherapy induces differentiation responses in AML and objective responses in myeloma.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 41
PURPOSE To determine the optimal induction chemotherapy regimen for younger adults with newly diagnosed AML without known adverse risk cytogenetics. PATIENTS AND METHODS One thousand thirty-three patients were randomly assigned to intensified (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin [FLAG-Ida]) or standard (daunorubicin and Ara-C [DA]) induction chemotherapy, with one or two doses of gemtuzumab ozogamicin (GO). The primary end point was overall survival (OS). RESULTS There was no difference in remission rate after two courses between FLAG-Ida + GO and DA + GO (complete remission [CR] + CR with incomplete hematologic recovery 93% v 91%) or in day 60 mortality (4.3% v 4.6%). There was no difference in OS (66% v 63%; P = .41); however, the risk of relapse was lower with FLAG-Ida + GO (24% v 41%; P < .001) and 3-year event-free survival was higher (57% v 45%; P < .001). In patients with an NPM1 mutation (30%), 3-year OS was significantly higher with F
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies - 6 month(s) ago
Nicosia et al. find that CCS1477 (inobrodib), an EP300/CBP bromodomain inhibitor, induces cell-cycle arrest and differentiation in hematologic malignancy models through disrupting EP300/CBP recruitment to enhancer networks occupied by critical transcription factors. In patients with relapsed/refractory disease, CCS1477 monotherapy induces differentiation responses in AML and objective responses in myeloma.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial - 9 month(s) ago
Liposomal daunorubicin and cytarabine (CPX-351) improved overall survival (OS) compared with 7+3 chemotherapy in older patients with secondary acute m…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Randomised Comparison of CPX-351 and FLAG-Ida in Adverse Karyotype AML and High-Risk MDS: The UK NCRI AML19 Trial - 12 month(s) ago
Key Points. In high-risk AML and MDS CPX-351 did not improve response or survival compared to FLAG-Ida but produced better relapse-free survivalIn the explorato
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Iomab-B Shows Significant Improvement in R/R AML Over Chemotherapy Prior to Allogeneic HCT - 1 year(s) ago
In findings from the phase 3 SIERRA trial, Iomab-B-based conditioning for patients with relapsed or refractory acute myeloid leukemia provided significant efficacy and tolerable safety results over the current standard of care.
Source: Targeted OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Latest opportunities - 1 year(s) ago
See the latest job opportunities at The Christie, including cancer nursing roles and admin roles working in the NHS.
Source: www.christie.nhs.ukCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Steve Barclay accused of ‘wasting months’ by failing to meet unions and being dismissive of their demands for improved pay
Source: the GuardianCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
UK falls from fourth to 10th place in phase III trials amid ‘ossified’ bureaucracy and stretched health service
Source: the GuardianCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Haematology Resident Doctor at The Christie Private Care - The Christie NFT , Manchester, Greater Manchester job with HCA Healthcare UK | 172815 - 1 year(s) ago
Resident Doctor Haematology. The Christie Private Care – Manchester, Salary up to £71,000 dependent upon skills and experience Full Time or Part Time
Source: BMJ CareersCategories: Hem/Oncs, Latest HeadlinesTweet
RT @Wang_Yu_Hung: Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies https://t.co/PGXNAEUMdf #leusm…